Moreover, over the past few years, several other novel targeted therapies have been approved for cancer treatment, including drugs with new targets (i.e., CDK4/6 inhibitors), mutation targeting drugs (i.e., the EGFR T790M targeting osimertinib), drugs with multiple targets (i.e., the EGFR/HER2 dual inhibitor neratinib), and drug combinations (i.e., encorafenib/binimetinib and dabrafenib/trametinib). The gene discussed is EGFR; the disease is cancer.